With these limitations in mind, here we describe the development and validation of a new HER2DX assay, a single 27-gene expression and clinical feature-based classifier able to provide two independent scores to predict both long-term prognosis and pCR likelihood in HER2-positive early breast cancer patients. Here, ERBB2 is linked to breast carcinoma.